Semaglutide Patent Expiry and the Emerging Generics Opportunity Globally
The semaglutide patent expiry is becoming one of the most discussed developments in the global pharmaceutical industry. It marks a structural shift in the diabetes and obesity treatment market. For years semaglutide based therapies have remained under strong patent protection which allowed premium pricing and limited competition. As patent protection gradually weakens the market is […]
Semaglutide Patent Expiry and the Emerging Generics Opportunity Globally Read More »





